Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane
Outlines Impact Of China Zero-COVID Policy
Executive Summary
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.